New trends in epidermal growth factor receptor-directed monoclonal antibodies

Immunotherapy

Volumn 1, Issue 6, 2009, Pages 965-982

  Markman, Ben ^a   Capdevila, Jaume ^a   Elez, Elena ^a   Tabernero, Josep ^a,b  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cancer; Cetuximab; EGF receptor; KRAS; Matuzumab; Monoclonal antibody; Panitumumab

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MATUZUMAB; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED;

ACNE; ALLERGIC REACTION; ASTHENIA; BLOOD PRESSURE; BREAST CANCER; BRONCHOSPASM; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; ESOPHAGEAL ADENOCARCINOMA; FEVER; GENETIC ENGINEERING; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPOMAGNESEMIA; INFECTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA AND VOMITING; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SURVIVAL;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROTEIN ENGINEERING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77953389316     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.66     Document Type: Review

References (116)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
2. Cohen S: The stimulation of epidermal proliferation by a specific protein (EGF). Dev. Biol. 12(3), 394-407 (1965).
3. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21(14), 2787-2799 (2003).
4. Citri A, Yarden Y: EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7(7), 505-516 (2006). • Elegant review of signal transduction using a more comprehensive, broad-based approach.
5. Ullrich A, Coussens L, Hayflick JS et al.: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309(5967), 418-425 (1984). (Pubitemid 14102443)
6. Ogiso H, Ishitani R, Nureki O et al.: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110(6), 775-787 (2002). (Pubitemid 35291060)
7. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284(1), 31-53 (2003).
8. Wells A: EGF receptor. Int. J. Biochem. Cell Biol. 31(6), 637-643 (1999).
9. Harris RC, Chung E, Coffey RJ: EGF receptor ligands. Exp. Cell Res. 284(1), 2-13 (2003).
10. Yarden Y: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37 (Suppl. 4), S3-S8 (2001).
11. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49-139 (1998).
12. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002).
13. Alroy I, Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410(1), 83-86 (1997). (Pubitemid 27283389)
14. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606-619 (2006).
15. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137 (2001).
16. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94(5), 1593-1611 (2002).
17. Brabender J, Danenberg KD, Metzger R et al.: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 7(7), 1850-1855 (2001).
18. Wikstrand CJ, Hale LP, Batra SK et al.: Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55(14), 3140-3148 (1995).
19. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD: Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. 324 (Pt 3), 855-861 (1997).
20. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
21. Morrison S, Oi V: Chimeric immunoglobulin genes. In: Chimeric Immunoglobulin Genes. Honjo T, Alt F, Rabbitts T (Eds). Academic Press, London, UK 260-274 (1989).
22. Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 332(6162), 323-327 (1988).
23. Green LL, Hardy MC, Maynard-Currie CE et al.: Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. 7(1), 13-21 (1994).
24. Jakobovits A, Vergara GJ, Kennedy JL et al.: Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production. Proc. Natl Acad. Sci. USA 90(6), 2551-2555 (1993).
25. Weiner LM: Fully human therapeutic monoclonal antibodies: J. Immunother. 29(1), 1-9 (2006).
26. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1(11), 1311-1318 (1995).
27. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1(5), 511-529 (1983).
28. Herbst RS, Kim ES, Harari PM: IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin. Biol. Ther. 1(4), 719-732 (2001).
29. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56(16), 3666-3669 (1996). (Pubitemid 26272010)
30. Perrotte P, Matsumoto T, Inoue K et al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5(2), 257-265 (1999).
31. Huang SM, Li J, Harari PM: Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol. Cancer Ther. 1(7), 507-514 (2002).
32. Huang SM, Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6(6), 2166-2174 (2000).
33. Baselga J, Pfister D, Cooper MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000).
34. th Annual Meeting of the American Society of Clinical Oncology. San Francisco, CA, USA, May 12-15 2001.
35. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin. Oncol. 22(7), 1201-1208 (2004). (Pubitemid 41079832)
36. Cunningham D, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004). •• Landmark study leading to regulatory approval of cetuximab in metastatic colorectal cancer (mCRC).
37. Jonker DJ, O'Callaghan CJ, Karapetis CS et al.: Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040-2048 (2007). •• Landmark study leading to regulatory approval of cetuximab in mCRC.
38. th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, May 18-21 2002.
39. Folprecht G, Lutz MP, Schoffski P et al.: Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 17(3), 450-456 (2006).
40. th Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, June 2-6 2006.
41. th Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, June 2-6 2006.
42. th Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, June 2-6 2006.
43. Tabernero J, Van Cutsem E, Diaz-Rubio E et al.: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25(33), 5225-5232 (2007).
44. Arnold D, Hohler T, Dittrich C et al.: Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a Phase Ib/II study of the AIO GI Group. Ann. Oncol. 19(8), 1442-1449 (2008).
45. Borner M, Koeberle D, Von Moos R et al.: Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized Phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann. Oncol. 19(7), 1288-1292 (2008).
46. Bokemeyer C, Bondarenko I, Makhson A et al. : Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009).
47. Raoul JL, Van Laethem JL, Peeters M et al.: Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part Phase I/II study. BMC Cancer. 9, 112 (2009).
48. Van Cutsem E, Kohne CH, Hitre E et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
49. Sobrero AF, Maurel J, Fehrenbacher L et al.: EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(14), 2311-2319 (2008).
50. th Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, USA, June 2-6 2006.
51. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J. Natl Cancer Inst. 90(9), 675-684 (1998).
52. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25(4), 527-533 (2004).
53. Lievre A, Bachet JB, Le Corre D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006). • First description of KRAS as a negative predictor of efficacy when using monoclonal antibodies (mAbs) targeting EGF receptor (EGFR).
54. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67(6), 2643-2648 (2007).
55. Di Fiore F, Blanchard F, Charbonnier F et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer. 96(8), 1166-1169 (2007).
56. Khambata-Ford S, Garrett CR, Meropol NJ et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 15(11), 3230-3237 (2007).
57. Lievre A, Bachet JB, Boige V et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26(3), 374-379 (2008).
58. De Roock W, Piessevaux H, De Schutter J et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19(3), 508-515 (2008).
59. Cappuzzo F, Varella-Garcia M, Finocchiaro G et al.: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br. J. Cancer. 99(1), 83-89 (2008).
60. Amado RG, Wolf M, Peeters M et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
61. Karapetis CS, Khambata-Ford S, Jonker DJ et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
62. Ciardiello F, Bianco R, Damiano V et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6(9), 3739-3747 (2000).
63. Shaheen RM, Ahmad SA, Liu W et al.: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer. 85(4), 584-589 (2001).
64. Tabernero J: The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5(3), 203-220 (2007).
65. Saltz LB, Lenz HJ, Kindler HL et al.: Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25(29), 4557-4561 (2007).
66. Tol J, Koopman M, Cats A et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360(6), 563-572 (2009).
67. Folprecht G, Gruenberger T, Hartmann J et al.: Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). Presented at: ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA, January 15-17 2009.
68. Huang SM, Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 17(3), 259-269 (1999).
69. Robert F, Ezekiel MP, Spencer SA et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19(13), 3234-3243 (2001).
70. Bonner JA, Harari PM, Giralt J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl. J. Med. 354(6), 567-578 (2006). •• Landmark study leading to approval of cetuximab in squamous cell cancer of the head and neck (SCCHN).
71. Vermorken JB, Trigo J, Hitt R et al.: Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25(16), 2171-2177 (2007).
72. Baselga J, Trigo JM, Bourhis J et al.: Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23(24), 5568-5577 (2005). •• Landmark study leading to approval of cetuximab in SCCHN.
73. Vermorken JB, Mesia R, Rivera F et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008).
74. Rosell R, Robinet G, Szczesna A et al.: Randomized Phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19(2), 362-369 (2008).
75. Thienelt CD, Bunn PA Jr, Hanna N et al.: Multicenter Phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 23(34), 8786-8793 (2005).
76. Butts CA, Bodkin D, Middleman EL et al.: Randomized Phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J. Clin. Oncol. 25(36), 5777-5784 (2007).
77. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, May 30-June 3 2008.. • First data showing survival advantage of mAbs against EGFR in non-small-cell lung cancer.
78. Carey LA, Rugo HS, Marcom PK et al.: TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, May 30-June 3 2008.
79. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, May 30-June 3 2008.
80. Xiong HQ, Rosenberg A, LoBuglio A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol. 22(13), 2610-2616 (2004).
81. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, June 1-5 2007.
82. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, June 1-5 2007.
83. Han SW, Oh DY, Im SA et al.: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br. J. Cancer. 100(2), 298-304 (2009).
84. Zhang X, Xu J, Shen L et al.: A Phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer. Presented at: ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA, January 15-17 2009.
85. Kim C, Lee J, Ryu M et al.: A prospective Phase II study of cetuximab in combination with capecitabine and oxaliplatin (XELOX) in patients with metastatic and/or recurrent advanced gastric cancer. Presented at: ASCO Gastrointestinal Cancers Symposium. Orlando, FL, USA, January 15-17 2009.
86. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, May 30-June 3 2008.
87. Motzer RJ, Amato R, Todd M et al.: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest. New Drugs 21(1), 99-101 (2003). (Pubitemid 36628489)
88. Kurtz JE, Hardy-Bessard AC, Deslandres M et al.: Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a Phase II GINECO trial. Gynecol. Oncol. 113(1), 16-20 (2009).
89. Yang XD, Jia XC, Corvalan J R, Wang P, Davis CG, Jakobovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59(6), 1236-1243 (1999). (Pubitemid 29136253)
90. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 38(1), 17-23 (2001).
91. Weiner LM, Belldegrun AS, Crawford J et al.: Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin. Cancer Res. 14(2), 502-508 (2008).
92. Hecht JR, Patnaik A, Berlin J et al.: Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 110(5), 980-988 (2007). (Pubitemid 47312862)
93. Van Cutsem E, Peeters M, Siena S et al.: Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658-1664 (2007). •• Registration study for panitumumab as monotherapy in mCRC.
94. Allegra CJ, Jessup JM, Somerfield MR et al.: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009). •• Summary statement of relevance of and need to assess KRAS mutation prior to EGFR mAb use in mCRC.
95. Hecht JR, Mitchell E, Chidiac T et al.: A randomized Phase HIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27(5), 672-680 (2009).
96. th Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA, USA, June 5-8 2004.
97. Rowinsky EK, Schwartz GH, Gollob JA et al.: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22(15), 3003-3015 (2004).
98. th American Association for Cancer Research Annual Meeting. Washington, DC, USA, July 11-14 2003.
99. Vanhoefer U, Tewes M, Rojo F et al.: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 22(1), 175-184 (2004).
100. Seiden MV, Burris HA, Matulonis U et al.: A Phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol. Oncol. 104(3), 727-731 (2007).
101. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, May 31-June 3 2003.
102. Peeters M, Siena S, Van Cutsem E et al.: Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115(7), 1544-1554 (2009).
103. th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, June 1-5 2007. • Proof-of-principle study prospectively demonstrating the correlation between cetuximab associated skin toxicity and efficacy.
104. Erbitux®(cetuximab). Package insert. New York: ImCIone Systems Inc. and Princeton, NJ, USA: Bristol-Myers Squibb Company (2007).
105. Chung CH: Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13(6), 725-732 (2008).
106. Chung CH, Mirakhur B, Chan E et al.: Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N. Engl. J. Med. 358(11), 1109-1117 (2008).
107. Vectibix®(panitumumab). Package insert. Thousand Oaks, CA, USA: Amgen Inc. (2007).
108. Tejpar S, Piessevaux H, Claes K et al.: Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 8(5), 387-394 (2007). (Pubitemid 46621761)
109. Di Nicolantonio F, Martini M, Molinari F et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705-5712 (2008). • Demonstrating BRAF mutations also predicts for resistance to EGFR mAbs.
110. th American Association for Cancer Research Annual Meeting. Denver, CO, USA, April 18-22 2009.
111. Jhawer M, Goel S, Wilson AJ et al.: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 68(6), 1953-1961 (2008).
112. Frattini M, Saletti P, Romagnani E et al.: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 97(8), 1139-1145 (2007). (Pubitemid 47587019)
113. Loupakis F, Pollina L, Stasi I et al.: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol. 27(16), 2622-2629 (2009).
114. Perrone F, Lampis A, Orsenigo M et al.: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 20(1), 84-90 (2009).
115. Vectibix® in combination with chemotherapy significantly improved progression-free survival in first-line metastatic colorectal cancer. Press release. http://wwwext.amgen.com/media/media-pr-detail.jsp?releaseID=1318284
116. Vectibix® significantly improved progression-free survival in second-line treatment of KRAS wild-type metastatic colorectal cancer. Press release. http://wwwext.amgen.com/media/media-pr-detail.jsp?year= 2009&releaseID=1321626